APA (7th ed.) Citation

Liu, T., Purser, M., Gong, C., Elsea, D., Niehoff, N., Dlotko, E., . . . Samyshkin, Y. (2024). EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective. Value in Health, 27(6), S112. https://doi.org/10.1016/j.jval.2024.03.599

Chicago Style (17th ed.) Citation

Liu, T., M. Purser, C. Gong, D. Elsea, N. Niehoff, E. Dlotko, K. Migliaccio-Walle, and Y. Samyshkin. "EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective." Value in Health 27, no. 6 (2024): S112. https://doi.org/10.1016/j.jval.2024.03.599.

MLA (9th ed.) Citation

Liu, T., et al. "EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective." Value in Health, vol. 27, no. 6, 2024, p. S112, https://doi.org/10.1016/j.jval.2024.03.599.